Once-monthly Invega Sustenna as good as bi-weekly Risperdal Consta for schizophrenia
This article was originally published in Scrip
Executive Summary
A Phase III head-to-head trial in schizophrenia has shown that Johnson & Johnson's antipsychotic drug Invega Sustenna (paliperidone) is non-inferior to its older, more-frequently dosed product, Risperdal Consta (risperidone).